87 related articles for article (PubMed ID: 22897844)
41. Emerging molecular networks in Burkitt's lymphoma.
Mangani D; Roberti A; Rizzolio F; Giordano A
J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
[TBL] [Abstract][Full Text] [Related]
42. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
43. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
44. MINCR is not a MYC-induced lncRNA.
Hart JR; Weinberg MS; Morris KV; Roberts TC; Janda KD; Garner AL; Vogt PK
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E496-7. PubMed ID: 26811502
[No Abstract] [Full Text] [Related]
45. New functions for PI3K in the control of cell division.
Kumar A; Carrera AC
Cell Cycle; 2007 Jul; 6(14):1696-8. PubMed ID: 17598985
[TBL] [Abstract][Full Text] [Related]
46. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.
Morton JP; Sansom OJ
Mol Oncol; 2013 Apr; 7(2):248-58. PubMed ID: 23523308
[TBL] [Abstract][Full Text] [Related]
47. Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Miscia S; di Baldassarre A; Rana RA; Pucci AM; Cataldi A
Cell Struct Funct; 1998 Feb; 23(1):17-22. PubMed ID: 9639026
[TBL] [Abstract][Full Text] [Related]
48. Rapid Death of Follicular B Cells and Burkitt Lymphoma Cells Effectuated by Xbp1s.
Chen YT; Kung JT
J Immunol; 2020 Jun; 204(12):3236-3247. PubMed ID: 32376649
[TBL] [Abstract][Full Text] [Related]
49. Hepatobiliary and Pancreatic: Burkitt lymphoma mimicking IgG4-related disease.
Azuma S; Kurita A; Yazumi S
J Gastroenterol Hepatol; 2018 Oct; 33(10):1694. PubMed ID: 29808497
[No Abstract] [Full Text] [Related]
50. Correlation of the thermosensitivity of cells to their malignant potential.
Giovanella BC; Stehlin JS; Yim SO
Ann N Y Acad Sci; 1980; 335():206-14. PubMed ID: 6931519
[No Abstract] [Full Text] [Related]
51. SnapShot: diffuse large B cell lymphoma.
Pasqualucci L; Dalla-Favera R
Cancer Cell; 2014 Jan; 25(1):132-132.e1. PubMed ID: 24434215
[No Abstract] [Full Text] [Related]
52. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
53. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
[TBL] [Abstract][Full Text] [Related]
54. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry.
Dominguez-Sola D; Victora GD; Ying CY; Phan RT; Saito M; Nussenzweig MC; Dalla-Favera R
Nat Immunol; 2012 Nov; 13(11):1083-91. PubMed ID: 23001145
[TBL] [Abstract][Full Text] [Related]
55. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
56. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
Amato T; Abate F; Piccaluga P; Iacono M; Fallerini C; Renieri A; De Falco G; Ambrosio MR; Mourmouras V; Ogwang M; Calbi V; Rabadan R; Hummel M; Pileri S; Leoncini L; Bellan C
Am J Clin Pathol; 2016 Jan; 145(1):116-27. PubMed ID: 26712879
[TBL] [Abstract][Full Text] [Related]
57. Correlation between the protein expression of A-kinase anchor protein 95, cyclin D3 and AKT and pathological indicators in lung cancer tissues.
Yu X; Yuan Y; Zhi X; Teng B; Chen X; Huang Q; Chen Y; Guan Z; Zhang Y
Exp Ther Med; 2015 Sep; 10(3):1175-1181. PubMed ID: 26622460
[TBL] [Abstract][Full Text] [Related]
58. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
[TBL] [Abstract][Full Text] [Related]
59. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.
Vaqué JP; Martínez N; Batlle-López A; Pérez C; Montes-Moreno S; Sánchez-Beato M; Piris MA
Haematologica; 2014 Feb; 99(2):222-31. PubMed ID: 24497559
[TBL] [Abstract][Full Text] [Related]
60. PI3K and cancer: lessons, challenges and opportunities.
Fruman DA; Rommel C
Nat Rev Drug Discov; 2014 Feb; 13(2):140-56. PubMed ID: 24481312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
